Comparison of Intrathecal Cilostazol and Nimodipine Treatments in Subarachnoid Hemorrhage: An Experimental Study in Rabbits

Önal, Mehmet Bülent; Bilginer, Burçak; Narin, Fırat; Ziyal, Ibrahim M.; Söylemezoğlu, Figen; Özgen, Tunçalp

doi:10.1007/978-3-7091-0356-2_9

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to calcium channel antagonists, other vasodilators that are currently being studied include milrinone, 30,32 nitric oxide, 33 magnesium sulfate, 57 cilostazol, 58 and glyceryl trinitrate. 59 Milrinone is a phosphodiesterase-3 inhibitor that has been proven to be safe and feasible for the prevention of DCI and in the period following confirmed vasospasm in a clinical setting.…”

Section: Calcium Channel Antagonistsmentioning

confidence: 99%

Update on intrathecal management of cerebral vasospasm: a systematic review and meta-analysis

Grossen

Ernst

Bauer

2022

Neurosurgical Focus

View full text Add to dashboard Cite

OBJECTIVE Aneurysmal subarachnoid hemorrhage (aSAH) accounts for a relatively small portion of strokes but has the potential to cause permanent neurological deficits. Vasospasm with delayed ischemic neurological deficit is thought to be responsible for much of the morbidity associated with aSAH. This has illuminated some treatment options that have the potential to target specific components of the vasospasm cascade. Intrathecal management via lumbar drain (LD) or external ventricular drain (EVD) offers unique advantages in this patient population. The aim of this review was to provide an update on intrathecal vasospasm treatments, emphasizing the need for larger-scale trials and updated protocols using data-driven evidence. METHODS A search of PubMed, Ovid MEDLINE, and Cochrane databases included the search terms (subarachnoid hemorrhage) AND (vasospasm OR delayed cerebral ischemia) AND (intrathecal OR intraventricular OR lumbar drain OR lumbar catheter) for 2010 to the present. Next, a meta-analysis was performed of select therapeutic regimens. The primary endpoints of analysis were vasospasm, delayed cerebral ischemia (DCI), cerebral infarction, and functional outcome. RESULTS Twenty-nine studies were included in the analysis. There were 10 studies in which CSF drainage was the primary experimental group. Calcium channel antagonists were the focus of 7 studies. Fibrinolytics and other vasodilators were each examined in 6 studies. The meta-analysis included studies examining CSF drainage via LD (n = 4), tissue plasminogen activator in addition to EVD (n = 3), intraventricular nimodipine (n = 2), and cisternal magnesium (n = 2). Results showed that intraventricular nimodipine decreased vasospasm (OR 0.59, 95% CI 0.37–0.94; p = 0.03). Therapies that significantly reduced DCI were CSF drainage via LD (OR 0.47, 95% CI 0.25–0.88; p = 0.02) and cisternal magnesium (OR 0.27, 95% CI 0.07–1.02; p = 0.05). CSF drainage via LD was also found to significantly reduce the incidence of cerebral infarction (OR 0.35, 95% 0.24–0.51; p < 0.001). Lastly, functional outcome was significantly better in patients who received CSF drainage via LD (OR 2.42, 95% CI 1.39–4.21; p = 0.002). CONCLUSIONS The authors’ results showed that intrathecal therapy is a safe and feasible option following aSAH. It has been shown to attenuate cerebral vasospasm, reduce the incidence of DCI, and improve clinical outcome. The authors support the use of intrathecal management in the prevention and rescue management of cerebral vasospasm. More randomized controlled trials are warranted to determine the best combination of pharmaceutical agents and administration route in order to formulate a standardized treatment approach.

show abstract